The expanded agreement now includes North and South American territories such as Canada, Mexico and Brazil, in addition to the US.
As per the new agreement, Arena is eligible to receive increased payments based upon Eisai’s net sales of lorcaserin in the US as well as North and South American territories.
Arena, in addition, will receive an upfront payment and is eligible to receive regulatory and development milestone payments.
Eisai president and chief executive officer Lonnel Coats said, "Through this expanded agreement, we believe Eisai has an opportunity to help address the significant and growing need for medical obesity treatments by bringing a potential new option to physicians and patients throughout the Americas."
Arena president and chief executive officer Jack Lief said the expanded commercialization agreement further supports the company’s belief in the medical potential of lorcaserin in the US and beyond.